Linaclotide: Uses, Evidence, and Side Effects

Key takeaways

• Linaclotide is a guanylate cyclase-C agonist sold under the brand name Linzess.
• It is approved for irritable bowel syndrome with constipation, chronic idiopathic constipation, and functional constipation in select age groups.
• The label carries a boxed warning.
• More than 60 registered trials have studied linaclotide, spanning original approval work and newer applications.
• Diarrhoea and constipation are the most frequently reported adverse events in post-marketing safety reports.

What linaclotide is

Linaclotide is a peptide that acts as a guanylate cyclase-C (GC-C) agonist, a class of drug that works locally in the gut rather than throughout the body. It is structurally related to human guanylin and uroguanylin, natural signaling molecules found in the intestine. Linaclotide and its active metabolite bind to GC-C receptors on the luminal surface of the intestinal lining. This binding raises cyclic GMP levels inside and outside the cells, which stimulates the intestine to secrete chloride and bicarbonate, drawing fluid into the bowel.

What linaclotide is approved for

Linaclotide, marketed as Linzess, is approved for three related conditions. These include irritable bowel syndrome with constipation (IBS-C) in adults and in children 7 years of age and older, chronic idiopathic constipation (CIC) in adults, and functional constipation in children 2 years of age and older. The label carries a boxed warning, which prescribers and caregivers should review directly.

What the evidence shows

Linaclotide has been studied in more than 60 registered clinical trials. One completed trial evaluated its safety in IBS-C patients in China. Newer, still-recruiting studies are exploring different applications, including a phase 1/2 trial testing linaclotide as part of colonoscopy bowel preparation and a separate trial combining linaclotide with virtual reality for IBS-C management.

Reported side effects

Post-marketing safety reports for linaclotide are dominated by gastrointestinal effects, most notably diarrhoea (4,580 reports) and constipation (1,937 reports), along with nausea (1,414), abdominal distension (1,134), and abdominal pain (1,041). A substantial number of reports also describe the drug as ineffective (4,430) or note off-label use (3,279), and fatigue was reported 1,143 times. These figures reflect the number of reports submitted to a safety database, not confirmed rates of occurrence or proof that linaclotide caused the event.